Moderna (MRNA) Net Margin (2017 - 2026)
Moderna's (MRNA) quarterly Net Margin came in at 539.31% in Q2 2026, up 4168.0% year-over-year from 12.64% in Q2 2025, and down 56.21% quarter-over-quarter from 345.24% in Q1 2026.
Powered by 
Analysis
Moderna (MRNA) Net Margin (2017 - 2026) Analysis & Trends
Moderna (MRNA) has reported Net Margin for 10 consecutive years, with 539.31% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Margin rose 4168.0% year-over-year to 539.31% in Q2 2026; TTM through Jun 2026 was 141.43%, a 4711.0% decrease from a year earlier, with the FY2025 full-year figure at 145.16%, down 3512.0% from the prior year.
- Net Margin was 539.31% for Q2 2026 at Moderna, down from 345.24% in the prior quarter.
- Over five years, Net Margin peaked at 60.29% in Q1 2022 and troughed at 899.07% in Q1 2025.
- A 5-year average of 237.6% and a median of 118.89% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin slumped 70784 bps in 2024 and soared 55383 bps in 2026, its largest moves.
- Over 5 years, Net Margin stood at 28.82% in 2022, then slumped by 73 bps to 7.72% in 2023, then slumped by 1602 bps to 115.94% in 2024, then decreased by 5 bps to 121.83% in 2025, then tumbled by 343 bps to 539.31% in 2026.
- The last three Net Margin figures came in at 539.31% (Q2 2026), 345.24% (Q1 2026), and 121.83% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.64 Bn | 192.65 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.82 Bn | 176.65 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 131.16 Bn | 123.31 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.67 Bn | 73.67 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 53.91 Bn | 48.77 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.12 Bn | 29.81 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.05 Bn | 29.05 Bn | 1.16 Mn | -20,152.98% |
| 10 | Insmed | 27.62 Bn | 26.46 Bn | 358.27 Mn | -3.12% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -539.31% |
| Mar 31, 2026 | -345.24% |
| Dec 31, 2025 | -121.83% |
| Sep 30, 2025 | -19.69% |
| Jun 30, 2025 | -580.99% |
| Mar 31, 2025 | -899.07% |
| Dec 31, 2024 | -115.94% |
| Sep 30, 2024 | 0.70% |
| Jun 30, 2024 | -530.71% |
| Mar 31, 2024 | -703.59% |
| Dec 31, 2023 | 7.72% |
| Sep 30, 2023 | -198.25% |
| Jun 30, 2023 | -401.16% |
| Mar 31, 2023 | 4.24% |
| Dec 31, 2022 | 28.82% |
| Sep 30, 2022 | 31.00% |
| Jun 30, 2022 | 46.26% |
| Mar 31, 2022 | 60.29% |
| Dec 31, 2021 | 67.51% |
| Sep 30, 2021 | 67.08% |